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University of California, Riverside, CaliforniaABSTRACT Two de novo protein design frameworks are applied to the discovery of new compstatin variants. One is based on
sequence selection and fold speciﬁcity, whereas the other approach is based on sequence selection and approximate binding
afﬁnity calculations. The proposed frameworks were applied to a complex of C3c with compstatin variant E1 and new variants
with improved binding afﬁnities are predicted and experimentally validated. The computational studies elucidated key positions in
the sequence of compstatin that greatly affect the binding afﬁnity. Positions 4 and 13 were found to favor Trp, whereas positions
1, 9, and 10 are dominated by Asn, and position 11 consists mainly of Gln. A structural analysis of the C3c-bound peptide analogs
is presented.INTRODUCTIONCompstatin is a synthetic 13-residue cyclic peptide that
inhibits the cleavage of C3 to C3a and C3b in the human
complement system and thus hinders complement activation.
It is cyclized by a disulfide bond between Cys2 and Cys12.
Compstatin is a novel drug candidate identified through the
screening of a phage-displayed random peptide library
with C3b, a proteolytically activated form of complement
C3, and was later truncated to its present 13-residue form
without loss of activity (1). Although complement activation
is part of normal inflammatory response, inappropriate
complement activation can cause host-cell damage, which
is the case in>25 pathological conditions, including autoim-
mune diseases, stroke, heart attack, Alzheimer’s disease, and
burn injuries (2). Compstatin has shown highly promising
results in numerous clinically relevant trials (1,3–10).
De novo design of compstatin variants aims at acquiring the
sequences corresponding to the best inhibitors to C3 and thus
the most potent drugs for diseases related to inappropriate
complement activation (11–15). Recent review articles on
de novo protein design present the advances and challenges
(16,17). Morikis et al. (13) studied compstatin sequences
using rational design, experimental combinatorial design,
and computational combinatorial design. A number of comp-
statin variants with known experimental relative activities
are presented in Table S1 in the Supporting Material. The
activities are relative to the native compstatin sequence.
The rational design of compstatin yielded an analog with
a fourfold higher activity than the native compstatin (18).
Using experimental combinatorial design, another compsta-
tin analog with fourfold increased activity was found
(peptide No. 6). In this design, the hydrophobic cluster and
the b-turn were kept, with the novel introduction of Trp at
position 9 (19). The introduction of this second Trp suggests
that Trp ring stacking may be important for the compstatinSubmitted July 20, 2009, and accepted for publication January 25, 2010.
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statin gave several analogs of compstatin with higher activity
than the native (11). These included peptides with an 11-fold
and 16-fold higher activity (peptides No. 7 and No. 8, respec-
tively) along with an extremely potent analog with 45-fold
higher activity (peptide No. 9, from here on referred to as
variant E1) (20). The computational design identified
another position (position 4) where an aromatic ring could
be placed to enhance ring stacking and activity. In this
case, Tyr was present in position 4 with Trp present in posi-
tion 7. In addition, Mallik et al. (20) studied compstatin
analogs with nonnatural amino acids.METHODS
Design template
The crystal structure of compstatin variant E1 in complex with complement
component C3c, recently elucidated by Janssen et al. (21) (Protein DataBank
(PDB) code: 2QKI), was used as the design template. They performed the
work on C3c instead of the whole C3 protein itself because C3c crystals
are easier to obtain and they diffract at a higher resolution than those of
C3. The structure of C3c complexed with the compstatin variant E1 is shown
in Fig. S1 in the Supporting Material.
As revealed by the structure, the binding site of the compstatin variant on
C3c is at macroglobulin domains 4 and 5. Because this is not confirmed as
the actual binding site of the compstatin variant E1 on C3, we only employ
the structure of the compstatin variant E1 in the C3c-compstatin complex as
the design backbone template for our de novo design of the inhibitor (see
Fig. 1). We believe this is the best model for C3-compstatin variant E1 inter-
action we can obtain thus far in the open literature. Both chains G and H
correspond to the compstatin variant E1 in the PDB file of the structure of
C3c-compstatin E1 complex. As we found that both chains are highly struc-
turally similar with an atom-to-atom root mean-square deviation of 0.405 A˚,
we only used chain G as the template for designing new compstatin variants.
In addition, the free compstatin structure was used (PDB code: 1A1P) for
comparison to the native compstatin sequence.
Mutation set
As the disulfide bridge was found to be essential for aiding the formation of
the hydrophobic cluster and prohibiting the termini from drifting apart, bothdoi: 10.1016/j.bpj.2010.01.057
FIGURE 1 A closeup view of the structure of compstatin variant E1
(ICVWQDWGAHRCT) in Fig. S1. It constitutes the design template for
our de novo design of the inhibitor.
FIGURE 2 Overview of the de novo design framework.
2338 Bellows et al.residues Cys2 and Cys12 were maintained. In addition, because the structure
of the type-I b-turn was not found to be a sufficient condition for activity, the
turn residues were fixed to be those of the parent compstatin sequence;
namely Gln5-Asp6-Trp7-Gly8. In fact, when stronger type I b-sequences
were constructed, which was supported by nuclear magnetic resonance
(NMR) data indicating that these sequences provided higher b-turn popula-
tions than compstatin, these sequences resulted in lower or no activity (18).
For similar reasons, Val3 was maintained throughout the computational
experiments.
Based on the structural and functional characteristics of those residues
involved in the hydrophobic cluster, positions 1, 4, and 13 were allowed
to select only from the hydrophobic amino acid set (A,F,I,L,M,W,V,Y).
In addition, this set included Threonine for position 13 to allow for the selec-
tion of the wild-type residue at this position. Thr is partially hydrophobic
because it has a methyl group and partially polar because it has a hydroxyl
group. For positions 9, 10, and 11, all residues were allowed, except for
Cysteine and Tryptophan. This mutation set leads to a problem with
complexity 3.0  106.
De novo design based on fold speciﬁcity
calculations
We first calculated the fold specificities of compstatin variants com-
plexed with C3c using our two-stage de novo design framework
(11,12,14,22,23). A graphical overview of the design process is depicted
in Fig. 2. The first stage produces a rank-ordered list of amino acid
sequences with the lowest energies in a flexible design template by solving
an integer programming sequence selection model (11,12,14,24). The
second stage calculates the specificities of the sequences to the fold based
on the full atomistic force field either through 1), the ASTRO-FOLD
approach (25–34) and deterministic global optimization (35–41); or 2), the
AMBER force field via a novel NMR structure refinement method (16,22).
The de novo protein design framework
Stage one: sequence selection
As the design backbone template has only one structure, the basic sequence
selection model (14) was used for obtaining amino acid sequences with the
lowest energies in the fold, although Fung et al. (14) have presented other
optimization models for flexible templates with multiple protein structures.
The basic model is an integer linear programming model of the formBiophysical Journal 98(10) 2337–2346minyj
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Set i ¼ 1, ., n defines the number of amino acid positions along the
backbone. At each position i, there can be a set of mutations represented
by j{i} ¼ 1,., mi, where, for the general case mi ¼ 20c i. The equivalent
sets kh i and lh j are defined, and k > i is required to represent all unique
pairwise interactions. Binary variables yi
j and yk
l are introduced to indicate
the possible mutations at a given position. Specifically, variable yi
j will be
one if position i is occupied by amino acid j, and zero otherwise. Similarly,
variable yk
l will assume the value of one if position k is taken by amino acid
l, and the value of zero otherwise. The composition constraints in the formu-
lation require that there is exactly one type of amino acid at each position.
Energy parameters Eik
jl indicate the pairwise interaction between amino
acid j at position i and amino acid l at position k and were calculated using
the centroid-centroid force field of Rajgaria et al. (42).
Using Eq. 1, we generated 1000 low energy sequences for which we
calculated the fold specificities in stage two.
Stage two: fold speciﬁcity calculations
Themethod described in Fung et al. (22) was used to generate an ensemble of
several hundred conformers for each of the 1000 sequences using CYANA
2.1 (43,44) and TINKER (45). The conformers are within the upper and
lower bounds on the Ca-Ca distances and dihedral angles obtained from
the native structure. The energies of the conformers for each sequence and
the native sequencewere used to calculate the fold specificity (see Supporting
New Compstatin Variants 2339Material). A workflow of stage two, detailing the programs used and the
number of structures that are input and output in each step, is given in Fig. S2.
De novo design based on approximate binding
afﬁnity ranking metric
The design of compstatin variants was also done using a novel de novo
design framework based on an approximate binding affinity (K*) ranking
metric. This novel de novo design framework also consists of two stages.
The first stage solves an integer programming sequence selection model
to generate a rank-ordered list of amino acid sequences with the lowest
energies (11,12,14,24). The second stage ranks the sequences based upon
approximate binding affinities. This second stage is more applicable when
the design template consists of a complex. Stage two of the novel design
framework utilizes programs from the Rosettaþþ package (47–49) for the
necessary structure and docking prediction and ensemble generation. Fig. 2
shows an overview of the novel de novo design framework.
The novel de novo protein design framework
Stage one: sequence selection
Stage one is the same as the one used in the de novo design based on fold
specificity calculations.
Stage two: approximate binding afﬁnity calculation
A novel approach to approximating the binding affinity of protein-ligand
complexes has been introduced by Lilien et al. (50). The approximate
binding affinity, K*, is given by Eq. 2, where qPL is the partition function
of the protein-ligand complex, qP is the partition function of the free protein,
and qL is the partition function of the free ligand:
K ¼ qPL
qPqL
: (2)
The partition functions are defined in Eq. 3, where sets B, F, and L contain
the rotamerically based conformations of the bound protein-ligand complex,
the free protein, and the free ligand, respectively. En is the energy of confor-
mation n, R is the gas constant, and T is the temperature:
qPL ¼
X
b˛B
e
Eb
RT ; qP ¼
X
f˛F
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RT ; qL ¼
X
‘˛L
e
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Because K* uses the Boltzmann probability distribution, it satisfies the
Ergodic hypothesis and can be proved to approximate the true binding
affinity, KA. K* will equal KA if K* is calculated using exact partition func-
tions. For an enzyme/ligand system, the true binding affinity is defined in
Eq. 4. At equilibrium, the chemical potentials mi of the complex, free protein,
and free ligand sum to zero (Eq. 5). By expressing the chemical potential in
terms of indistinguishable particles (Eq. 6) and substituting this into Eq. 5,
we obtain Eq. 7. Thus, the true binding affinity can be expressed as a ratio
of the individual species partition functions. The more accurate the partition
functions, the better KA is approximated:
KA ¼ ½PL½P½L; (4)
mP þ mL  mPL ¼ 0; (5)
mi ¼ kTln

qiðV; TÞ
Ni

; (6)
qPLðV; TÞ
qPðV; TÞqLðV; TÞ ¼
NPL
NPNL
¼ KA: (7)Fig. S2 provides a graphical depiction of the steps needed to calculate K*
and further details can be found in the Supporting Material. First, three-
dimensional structures of each sequence are generated using RosettaAbinitio
(47,51,52). For each sequence, 1000 peptide structures are generated. The
structures are then clustered based upon their f- and j-angles using
OREO (53, P. A. DiMaggio, S. R. McAllister, C. A. Floudas, X. J. Feng,
J. D. Rabinowitz, and H. A. Rabitz, unpublished). This groups together
similar structures. An average structure from each of the 10 largest
clusters, plus the overall lowest energy structure, are selected for docking.
RosettaDock (48,55,56) is used to dock each of the 11 peptide structures to
the target protein. For each docking run, 1000 docked conformers are gener-
ated. Finally, RosettaDesign (49) is used to generate the rotamerically based
conformation ensembles using the peptide structures from RosettaAbinitio,
the complex structures from RosettaDock, and the crystal structure of the
target protein as input structures for the free peptide, complex, and free
protein ensembles, respectively. Solvation effects are incorporated implicitly
in the energy functions that are used to drive each of the modeling steps
(sequence selection, structure prediction, docking, etc.). The Rosetta
programs use the Lazaridis-Karplus solvation model (57), which is based
on a Gaussian-shaped solvent exclusion.
The free peptide ensemble consists of 22,000 total structures (set L). One-
hundred-and-ten starting structures are obtained by selecting the 10 lowest-
energy structures from each of the 10 largest clusters plus the 10 overall
lowest-energy structures obtained from RosettaAbinitio. For each starting
structure, 200 rotamer conformers are generated, giving a final ensemble
of 22,000 structures. The ensemble incorporates both backbone flexibility
(by using 110 different backbone starting structures) and rotamer flexibility
(by generating 200 rotamer conformers per starting structure).
The complex ensemble also consists of 22,000 total structures (set B).
Again, 110 starting structures are used, this time by selecting the 10 lowest-
energy docked conformers from the 11 docking runs per sequence. Two-
hundred rotamer conformers are generated per starting structure. Flexibility
is taken into account by the various peptide backbone structures used (11
different backbones total), the various docked conformations (10 per peptide
backbone), and the rotamer conformers for each starting structure.
The free protein ensemble consists of only 2000 total structures (set F).
Because the target protein is so large (>1000 residues), it is computationally
infeasible to predict backbone structures. Therefore, the crystal structure of
the protein is used as the only starting structure and 2000 rotamer conforma-
tions are generated.
For the stage two calculations, we are not attempting to compare our pre-
dicted K* values with actual experimental binding affinities, but instead are
using it as a ranking metric to sort the sequences from stage one to elucidate
better binders. In fact, it is difficult to precisely compare the values of K* to
experimental binding affinities because K* is unitless. The partition func-
tions themselves are unitless.
RESULTS
Results for both stage one (run 1) and the top 10 sequences
with the highest fold specificities from stage two are shown
in Table S2 and Table 1, respectively.
The following suggested mutations versus the native
sequence of compstatin are observed from the sequences pre-
dicted based on fold specificities: I1(V/L/I), V4W, H9(Q/R),
H10(M/N/V/R), R11(R/N), and T13W. The preference of
Trp at positions 4 and 13 is dominant. Notice that the Trp
at position 4 is already present on compstatin variant E1,
which corresponds to 45-fold improvement in potency
over the native compstatin (20). As for position 13, a muta-
tion to Val was experimentally validated to be preferred
(11,46), whereas a more hydrophobic amino acid of Trp
might lead to even higher potency. The suggested mutationsBiophysical Journal 98(10) 2337–2346
TABLE 1 Top 10 sequences from stage one with the highest fold speciﬁcities (Run 1)
Sequence
Sequence selection
rank
Fold specificity
rank
Approximate binding
affinity rank
Position
K* 1 2 3 4 5 6 7 8 9 10 11 12 13
NCV-2 756 2 1 4.31  1002 I C V W Q D W G R N N C W
NCV-10 809 10 2 3.30  1002 V C V W Q D W G R V N C W
NCV-3 392 3 3 3.83  1004 L C V W Q D W G Q M R C W
Variant E1 n/a n/a 4 5.78  1006 I C V W Q D W G A H R C T
NCV-5 684 5 5 4.10  1007 W C V W Q D W G R N N C W
NCV-1 833 1 6 3.55  1007 V C V W Q D W G Q M R C W
NCV-8 867 8 7 9.69  1008 I C V W Q D W G Q I R C W
NCV-7 671 7 8 6.26  1009 F C V W Q D W G Q M R C W
NCV-4 659 4 9 3.51  1010 I C V W Q D W G Q V R C W
NCV-9 343 9 10 8.01  1011 I C V W Q D W G Q R N C W
NCV-6 539 6 11 6.88  1011 L C V W Q D W G Q R N C W
Native n/a n/a 12 4.27  1012 I C V V Q D W G H H R C T
Mutations are indicated in boldface.
2340 Bellows et al.of H9(Q/R) and H10(M/N/V/R) have not been experimen-
tally tested. For positions 1 and 11, the fold specificity results
suggest it might be favorable to keep the native residues.
Before using the sequences generated from stage one, stage
two of the novel design framework was tested on sequences
from the previous designs of compstatin (Table S1). The
goal was to predict, correctly, whether the compstatin variant
binds better or worse than the native. For all partition function
calculations, the sets B and L consisted of 22,000 configura-
tions, and the set F consisted of 2000 configurations.
The approximate binding affinity model is successful
because it provides theoretical predictions on binding, which
have been experimentally validated using surface plasmon
resonance (SPR) binding studies. Although the theoretical
algorithm ranks the predicted analogs with respect to the
native peptide, this ranking is only approximate and depends
on the theoretical details and parameterization of the algo-
rithm and the calculation setup. In addition, the theoretical
predictions are based on binding of compstatin analogs to
C3c, whereas the SPR studies are performed with the whole
C3. Thus, the success of the algorithm lays in its ability to
predict any new sequences with binding abilities. Further
optimization of the predicted sequences by incorporating
nonnatural amino acids (20) is expected to increase binding
affinities.
Of the sequences in Table S1, peptide Nos. 6, 7, 8, and 9
were correctly predicted to be better binders than the native,
and peptide Nos. 2 and 4 were correctly predicted to be
worse binders than the native. Peptide Nos. 1 and 3 were
incorrectly predicted to be better binders than the native.
There could be two reasons for this discrepancy. One is
that the experimental relative activity is based upon IC50
data. IC50 is a measure of the concentration of the peptide
required to obtain 50% inhibition of the target protein.
This is not the same as binding affinity, although the two
are related. The relationship between binding affinity and
IC50 also depends upon the concentration of the substrate
or ligand and the Hill coefficient. There can be cases where
a ligand has a higher binding affinity (or lower KD, inverse ofBiophysical Journal 98(10) 2337–2346binding affinity), but a higher IC50 when compared to
another ligand (58). Furthermore, the computational predic-
tions and SPR data are on binary systems, whereas any
immunological assay, in vitro or in vivo, are on nonbinary
systems, involving inhibitions of pathways or reactions.
Therefore, we cannot expect the data from binary systems
to correlate exactly with data from nonbinary systems. The
second reason for the discrepancy is that the rotamer
sampling is simply not high enough. If the rotamer space
could be perfectly sampled, the prediction of K* would be
exact. This, however, is computationally demanding. Our
method is also limited by the accuracy of the energy
functions used in the various Rosetta programs. Although
these are some of the best protein prediction and docking
methods available, any inherent limitations translate into
our calculations.
Looking closer at the sequences in Table S1, variant E1
has two mutations compared to the native (i.e., V4W and
H9A), and exhibits a 45-fold higher potency than the native
compstatin (20). The sequences proposed by Klepeis et al.
(11,12) show up to a 16-fold improvement in activity over
the native compstatin. Peptide No. 7 has three mutations
(i.e., V4Y, H9F, and T13V), whereas peptide No. 8 has
two mutations (i.e., V4Y and H9A) compared to the native
sequence. It is important to emphasize that the key common
element is the presence of a hydrophobic and aromatic amino
acid in position 4.
Approximate binding affinities of high-fold specificity
sequences were calculated to compare the ranking based
upon fold specificity and the ranking based upon approxi-
mate binding affinities. Table 1 shows the K* results. In
comparing the two ranking metrics, we find no correlation,
yet the sequences with high fold specificities are all predicted
to be better binders than the native sequence. All of the de-
signed sequences exhibit a higher binding affinity than the
native, and three of them, variants NCV-2, NCV-10, and
NCV-3 have higher approximate binding affinities than
variant E1. Variant NCV-2 has five mutations (V4W,
H9R, H10N, R11N, and T13W). Variant NCV-10 has six
New Compstatin Variants 2341mutations (I1V, V4W, H9R, H10V, R11N, and T13W).
Variant NCV-3 has five mutations (I1L, V4W, H9Q,
H10M, and T13W). The mutations among the 10 variants
are extremely similar. In all cases, positions 4 and 13 were
mutated to Trp and positions 9–11 were mainly mutated
to a set of polar amino acids. Note the consistency in position
9 (either Q or R) for these sequences and the dominance of
Asn in position 11. Many combinations of polar amino acids
at these positions are possible and examples of structural
analyses are given in Fig. S3 and Fig. S4. These sequences
are similar to variant E1 in position 4 and contain the same
dominance in positions 9–11 of polar amino acids. Variant
E1 also maintains the native Thr in position 13, while the
10 variants changed this residue to Trp.
Based upon these observations, the sequence selection
model (stage one) was run again, generating sequences
with mutations allowed only in positions 1, 9, 10, and 11.
Positions 9, 10, and 11 were allowed to select from the
hydrophilic amino acids (G,N,Q,H,K,R,D,E,S,T,P), while
position 1 was allowed to select from all amino acids. Trp
was specified in positions 4 and 13 and positions 2–3, 5–8,
and 12 were kept the same as in the native. Two-thousand
sequences were generated in total. Table S2 shows preferred
amino acid mutations (run 2) for each position.
Table 2 shows a selection of sequences from stage one for
which approximate binding affinities were calculated. The
sequences are ranked accordingly.
Upon closer examination of the 16 sequences, the muta-
tions chosen for two of the four positions are rather con-
served. Position 10 exhibited 13 mutations to Asn and two
to Lys. Position 11 exhibited 12 mutations to Gln and three
mutations to Lys. Positions 1 and 9 showed more variability
in the amino acids chosen, but in each case, there was one
dominant amino acid. The dominant amino acid in positionsTABLE 2 Top sequences from stage one with the highest approxim
Sequence
Sequence selection
rank
Approximate binding
affinity rank K*
SQ027 40 1 3.38  10þ01
SQ100 159 2 8.45  10þ00
SQ087 214 3 4.26  1002
SQ072 166 4 1.31  1002
SQ077 185 5 3.07  1003
SQ040 102 6 4.48  1004
SQ098 238 7 3.46  1004
SQ017 50 8 6.78  1005
SQ025 69 9 4.27  1005
SQ086 210 10 1.10  1005
Variant E1 n/a 11 5.78  1006
SQ023 59 12 6.73  1007
SQ024 65 13 4.35  1007
SQ059 144 14 1.50  1007
SQ055 133 15 2.95  1008
SQ046 112 16 2.06  1008
SQ088 213 17 1.11  1008
Native n/a 18 4.27  1012
Mutations are indicated in boldface.1 and 9 was Asn, with four of the 16 sequences choosing
that amino acid in each position. However, the two best
sequences show a mutation of Trp in position 1. These
sequences exhibit four Tryptophans. Among the 10 se-
quences that outperformed variant E1, position 10 exhibited
seven mutations to Asn. Position 11 exhibited seven muta-
tions to Gln and two mutations to Lys. Position 1 showed
more dominance for Asn, with three of the 10 sequences
choosing that amino acid, whereas position 9 showed less
dominance for Asn, with only one out of the 10 sequences
choosing that amino acid.
The effect of different docking programs was also exam-
ined and was found to have no effect on the final K* ranking.
Further details can be found in the Supporting Material.Experimental binding studies of select sequences
Three of the designed sequences were selected for synthesis
and determination of experimental binding using SPR. The
experiments were carried out using the biosensor Biacore
X100 (Biacore, Piscataway, NJ). The native compstatin,
variant E1, SQ027, SQ086, and SQ059 were synthesized
and immobilized on the sensor chip. Table S4 provides the
amino acid sequences that were synthesized. Eight polyeth-
ylene glycol blocks, followed by K-biotin, were added to the
amino acid sequences for Biacore. Seven different concen-
trations of C3 were used during the experiment: 1600 nM,
800 nM, 400 nM, 200 nM, 100 nM, 50 nM, and 25 nM.
The KD values were extracted by simultaneous fitting
of the 0–800 nM data. The 1600 nM were not used because
they showed some evidence of saturation. The data from the
experiments were fit to three models: 1:1 binding model,
two-state reaction model, and a heterogeneous ligand model.
The experimental bindings (KD) are reported in Table 3.ate binding afﬁnities (Run 2)
Position
1 2 3 4 5 6 7 8 9 10 11 12 13
W C V W Q D W G T N R C W
W C V W Q D W G Q T Q C W
N C V W Q D W G K K Q C W
D C V W Q D W G Q N Q C W
G C V W Q D W G G N Q C W
Q C V W Q D W G T N Q C W
K C V W Q D W G N N K C W
N C V W Q D W G H N K C W
N C V W Q D W G S N Q C W
Q C V W Q D W G Q N Q C W
I C V W Q D W G A H R C T
N C V W Q D W G E N Q C W
S C V W Q D W G N N Q C W
D C V W Q D W G T N K C W
P C V W Q D W G N K Q C W
P C V W Q D W G N N Q C W
G C V W Q D W G K N Q C W
I C V V Q D W G H H R C T
Biophysical Journal 98(10) 2337–2346
TABLE 3 Experimental binding results and stage two ranking
for four compstatin variants and the native compstatin
Sequence
Approximate binding
affinity rank KD (M) Model
Variant E1 11 0.19  1006 Two-state reaction
0.23  1006 1:1 binding
SQ059 14 0.74  1006 Two-state reaction
0.45  1006 1:1 binding
SQ027 1 0.76  1006 Two-state reaction
0.51  1006 1:1 binding
SQ086 10 0.99  1006 Two-state reaction
0.50  1006 1:1 binding
Native 18 1.26  1006 Two-state reaction
0.81  1006 1:1 binding
2342 Bellows et al.Values of KD for using both the two-state reaction model and
the 1:1 binding model are also reported. Based on our selec-
tion criteria for the quality of the fits (Rmax values, c
2 values,
and visual inspection of the fits and residuals), the two-state
reaction model is more appropriate to describe the data. In
Table 3, we also include the simplest 1:1 binding model
for comparison.
KD is the inverse of the binding affinity, KA, so a lower
value indicates a better binder. Based upon the experimental
data in Table 3, all four compstatin variant sequences bind
better to C3 than the native compstatin.
Effect of sampling on K* rank
Further computational experiments were performed on
SQ059, SQ086, SQ027, and variant E1 to investigate the
effect of sampling on the K* rank. These higher sampling
runs increased the number of peptides generated using Ro-
settaAbinitio from 1000 to 5000 and the number of docked
conformers generated using RosettaDock from 1000 to
5000. The ranking obtained using the higher sampling is
variant E1 > SQ086 > SQ059 > SQ027. This nearly
matches the experimental ranking, with only SQ086 out of
order.DISCUSSION
Computational ﬁndings
Two de novo protein design frameworks were presented and
applied to the design of novel compstatin variants.
Approximate binding affinity calculations were first
applied to a number of compstatin variants with known rela-
tive activities compared to the native compstatin. Although
most of the sequences were correctly predicted to be better
or worse binders than the native compstatin, two of the
sequences were not correctly predicted. As stated earlier,
this could be due to the fact that the relative activities are
based upon IC50 data, not binding affinity data, and although
there is a correlation between IC50 and binding affinity, they
are not an exact match. The incorrect predictions may also
point out some current limitations in the framework. TheBiophysical Journal 98(10) 2337–2346better we are able to sample the conformation space, the
better we can approximate the binding affinity.
Approximate binding affinities of 10 sequences with high
fold specificities were calculated to see how functional these
well-folded peptides are. Looking at Table 1, one sees that
every one of the designed sequences is ranked higher than
the native, with three of them (variants NCV-2, NCV-10,
and NCV-3) ranking higher than variant E1. However,
sequences with higher fold specificities do not necessarily
have higher approximate binding affinities than those with
lower fold specificities. Therefore, fold specificity calcula-
tions do not necessarily capture how functional a designed
peptide or protein will be, making the K* ranking a good
measure for validating the designed sequences.
Computational studies of the design of compstatin have
elucidated a number of key positions in the sequence that
greatly affect the binding of compstatin to C3c. These studies
identify Trp in positions 4 and 13. This is consistent with the
results found by Morikis et al. (13), indicating that ring
stacking and p-cation interactions may be important for
compstatin activity. Based upon these results, a second
design of compstatin was performed. Stage one generated
2000 sequences, allowing mutations only in positions 1, 9,
10, and 11, and fixing positions 4 and 13 as Trp. Stage
two calculations show that of the 16 sequences presented
all are ranked higher than the native compstatin.
The dependence of the ranking on the docking program
used was investigated by redoing the approximate binding
affinity calculations using another docking program,
HADDOCK.Whether we used RosettaDock or HADDOCK,
we still obtained the same ranking for the sequences, showing
the independence of the overall framework on the particular
docking program used.
Three sequences were selected for synthesis and experi-
mental validation of the binding affinity using Biacore
X100. The experimental results validate that the predicted
sequences are better binders than the native.
Finally, the effect of higher sampling on the three de-
signed sequences selected for experimental validation and
variant E1 was examined, showing that the sampling does
indeed affect the final ranking, and that higher sampling
ranks the sequences closer to the experimental rank. It should
be noted that even though higher sampling leads to an
increase in the computational requirement, it achieves the
goal of elucidating better binders than the native sequence.Structural analysis of the C3c-bound compstatin
variants
We have performed structural analysis of compstatin vari-
ants with higher predicted binding affinities in complex
with C3c. Fig. S3 shows the best binders from a selected
10 predictions of Table 2, using the structures of the
complexes and the structures of the individual compstatin
variants. The selected 10 predictions correspond to
New Compstatin Variants 2343approximate binding affinities in the range 1.11  1008 –
4.62  1002 (Table 2). There is a consensus binding site
in the b-chain of C3c, with small positional variability
(Fig. S3 A). The consensus binding site is similar to that of
the E1 variant, observed in the crystal structure (21). Interest-
ingly, there is orientational and conformational variability,
within the consensus binding site, in the selected 10 predic-
tions of compstatin variants. The orientational variability is
shown in Fig. S3, A and B, and the conformational variability
is shown in Fig. S3, C and D. These variabilities are not
unusual in binding. As Boehr and Wright (59) point out,
according to conformational selection hypothesis, before
binding the protein-ligand partners exist as ensembles of
conformations in dynamic equilibria. Conformational selec-
tion involves interactions of low-population and high-energy
conformers (60). Positional, orientational, and conforma-
tional variabilities are in line with this model. Indeed, for a
family of peptides with variable binding affinities, owed to
small sequence differences, it is the physicochemical proper-
ties of the replaced amino acids that contribute to differences
in conformational selection and the equilibrium of the bound
conformation.
Fig. S4 shows a complete analysis of positional, orienta-
tional, and conformational variabilities for the top 10 itera-
tions that led to the selected 10 binders. The relative
topologies of the selected 10 variants with respect to the
binding site in C3c are depicted in Fig. S3 A and their relative
topologies with respect to each other are depicted in Fig. S3,
A and B. The conformational variability includes random coil
conformations (three structures), b-hairpins (two structures),
and helical conformations (five structures) (Fig. S3, C and
D). Fig. S5 provides a Ramachandran plot analysis of the
secondary structures. In the two b-hairpin conformers and
in the random coil region of at least one helical conformer
a Type I b-turn is present in the segment Gln5-Gly8, as
was the case of free compstatin in solution and several of
its analogs in free state (18–20,61). Shifted b-turns are also
present in the three random coil conformers. Shifted or fused
b-turns are also consistent with NMR spectra of free comp-
statin analogs (18,20). A Type I b-turn is present in the struc-
ture of free E1 variant (20) but absent in the structure of the
E1 variant complexed with C3c (21). The helical conforma-
tions are short involving one or two helical turns (Fig. S3 D).
All five helical conformations involve the second-half of the
peptide sequences (Fig. S3 D), which is consistent with the
observation from previous NMR studies that Alanine at posi-
tion 9 introduces helical propensity (13,18,20). Two of the
helical conformations also involve a segment close to the
N-terminal. The helical conformations are stabilized by
backbone-backbone (i, iþ3) and (i, iþ4) hydrogen bonds,
which is consistent with the presence of 310- or a-helices.
There are two 310-helical turns in two structures, one alone
and another in combination with an a-helical turn, the re-
maining being a-helical turns. The b-hairpin conformations
are stabilized by the presence of up to four interstrand back-bone-backbone hydrogen bonds. Other fortuitous hydrogen
bonds involving backbone or side chains are also present
in some structures.
It is possible that the backbone conformation and orienta-
tion is dictated by the specific intermolecular side-chain
interactions, rather than an intrinsic structural propensity.
This is not unexpected, because free peptides in solution
are flexible and form ensembles of interconverting con-
formers (13,18,20,61–67). Binding occurs through confor-
mational selection of one free peptide conformation, not
necessarily of lowest free energy, followed by induced fit
within the binding site. The latter involves side-chain rear-
rangements for both peptide and target protein, possibly
small backbone motions, and exclusion of solvent molecules
from the binding interface. Conformational interconversion
has been observed before for parent compstatin using molec-
ular dynamics (64), involving the same conformations as
here: coil, b-hairpin, and helical. Actually, the calculated
motional amplitudes for interconversion were very small,
0.1–0.4 A˚. The same applied on free energies, which were
~2–11 kcal/mol, corresponding to gaining or losing approx-
imately three hydrogen bonds.
We have performed a side-chain analysis for the selected
10 compstatin variants in search for dominant sidechain-
sidechain intra- and intermolecular interactions that may sta-
bilize internally the peptides structures and the peptide-C3c
complexes. We focused first on the three Tryptophans, which
represent a novel finding of this article (to our knowledge),
and we extended our analysis to all side chains. Fig. S6 shows
the binding sites from the best binders of the selected 10
compstatin variants (Table 2), focusing on interactions of
Trp4, Trp7, and Trp13 with C3c amino acids within 3.5 A˚.
A complete analysis, not only of the three Tryptophans but
also of the other side chains within 5 A˚, is given in Table
S5. The choice of 3.5 A˚ and 5 A˚ was to identify salt bridges
or medium-range ionic interactions. Multiple interactions
are present within 5 A˚, involving hydrophobic contacts, inter-
actions between the Tryptophan ring p-electron system and
positive or negative charges of basic or acidic C3c side chains,
and hydrogen bonds. Although there are no obvious
consensus side-chain contacts, there are compensatory effects
involving the three Tryptophans. For example, when one
Tryptophan does not participate or has reduced contacts
with C3c, another Tryptophan has increased contacts with
C3c. This type of compensation may explain the slight varia-
tion of the consensus binding site and the orientational and
structural variability of the selected 10 compstatin variants.
The role of Trp4 is variable and depends on the peptide
sequence and the optimal physicochemical contacts it makes
with C3c. These involve hydrophobic clustering against
C3c amino acids and occasionally hydrogen-bonding and
p-cation interactions. The structural analysis of Fig. S3 and
Fig. S4 suggests a wealth of possible physicochemical inter-
actions, depending on the specific peptide sequences, secon-
dary and tertiary structures, and side-chain conformations.Biophysical Journal 98(10) 2337–2346
2344 Bellows et al.This is expected, given that the specifics of the sequence are
responsible for binding variability.
Table S6 presents an intermolecular hydrogen-bond
analysis. There are two-to-five intermolecular hydrogen
bonds per compstatin variant-C3c complex, which is compa-
rable to the five intermolecular hydrogen bonds in the E1
variant (PDB code: 2QKI (21)), calculated with the same
hydrogen-bond definition criteria (Table S6). Persistent
hydrogen bonds throughout our analysis of the selected
10 binders involve Trp4 (five structures and E1 variant)
and amino acid at position 1 (four structures and E1 variant).
Hydrogen bonds involving the side chain of Trp13 are
observed in two structures. It should be noted that Trp7
does not participate in hydrogen-bonding in our analysis,
although it shows a hydrogen bond in the E1 variant. Over-
all, our analysis shows 20 intermolecular hydrogen bonds
involving compstatin variant side chains and 12 involving
backbone, with backbone or side-chain partners in C3c.
Persistent amino acids of interaction on the C3c side are
Arg455 and Arg458 (five structures each).
Fig. S7 presents an analysis of intramolecular side-chain
conformational variability and intramolecular side-chain
contacts.
Overall, our data suggest that there is neither fixed confor-
mation nor fixed lock-and-key binding site-peptide complex.
This may be indicative of weak binding. Weak binding may
be supported by the absence of a C3c binding cavity and by
the fact that only 40% of the surface of the E1 variant is
buried in the crystal structure (21). According to experi-
mental data, the binding of compstatin to C3c is much
weaker than to C3b and C3 (3). For example, the binding
of parent compstatin to C3c was found to be 74-fold lower
than to C3 and the binding mechanism was proposed to be
different based on experimental data (i.e., involving biphasic
binding and local conformational changes (3)). A structural
analysis of the best binders of Table 1 demonstrates two
docking hits with alternative binding sites, but the majority
of the variants bind within the consensus binding site
(Fig. S8). Although hits with nonsignificant statistical
meaning are not unusual in docking studies, the possibility
of alternative binding sites may not be excluded. The pres-
ence of active analogs with conformational and orientational
variability and compensatory binding effects owed to the
presence of the three Tryptophans may be the novelty of
our data. This type of variability cannot be identified using
static crystallographic structures.SUPPORTING MATERIAL
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